会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • METHODS OF TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY
    • 治疗由氧化氮缺乏症引起的血管疾病的方法
    • US20090226407A9
    • 2009-09-10
    • US10692724
    • 2003-10-27
    • Joseph LoscalzoJoseph VitaMichael LobergManuel Worcel
    • Joseph LoscalzoJoseph VitaMichael LobergManuel Worcel
    • A61K38/43A01N43/04
    • A61K31/135A61K9/0056A61K9/7023A61K31/19A61K31/34A61K31/355A61K31/415A61K31/495A61K31/50A61K31/535A61K45/06A61K2300/00
    • The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and/or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The vascular diseases characterized by nitric oxide insufficiency include a cardiovascular disease and a disease resulting from oxidative stress.
    • 本发明提供治疗和/或预防以一氧化氮不足为特征的血管疾病的方法,其通过施用治疗有效量的至少一种亚硝化血管紧张素转换酶抑制剂,亚硝化β-肾上腺素能阻断剂,亚硝化胆固醇降低剂,亚硝化钙通道阻断剂,亚硝化 内皮素拮抗剂,亚硝化血管紧张素II受体拮抗剂,亚硝化肾素抑制剂和任选的至少一种用于治疗心血管疾病的化合物,和/或至少一种抗氧化剂或其药学上可接受的盐,和/或至少一种可以转移的化合物 或释放一氧化氮,提高内源性内源性舒张因子水平,刺激一氧化氮的内源性合成,或是一氧化氮合成酶的底物。 抗氧化剂可优选为肼屈嗪化合物或其药学上可接受的盐。 捐赠,转移或释放一氧化氮的化合物提高内源性内皮衍生的松弛因子水平,刺激一氧化氮的内源性合成,或者是一氧化氮合酶的底物可优选为硝酸异山梨酯和/或一硝酸异山梨酯。 以一氧化氮不足为特征的血管疾病包括心血管疾病和由氧化应激引起的疾病。